Comparative Pharmacology
Head-to-head clinical analysis: ARANELLE versus ENSKYCE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARANELLE versus ENSKYCE.
ARANELLE vs ENSKYCE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of ethinyl estradiol and norethindrone suppresses gonadotropin release, inhibiting ovulation and altering cervical mucus and endometrial receptivity.
ENSKYCE (fospropofol disodium) is a prodrug of propofol. It is hydrolyzed by alkaline phosphatases to release propofol, which acts as a positive allosteric modulator of GABA-A receptors, enhancing chloride conductance and producing sedation and anesthesia.
One tablet (norethindrone 1 mg and ethinyl estradiol 20 mcg) orally once daily for 21 days, followed by 7 days of placebo.
2 g IV every 8 hours over 5 hours on days 1-3 of each 21-day cycle
None Documented
None Documented
Terminal half-life 12-14 hours; steady-state achieved within 2-3 days; clinical context supports once-daily dosing
12 hours (terminal); allows once-daily dosing in most patients
Renal 50-60% as metabolites (sulfate and glucuronide conjugates), fecal 30-40%, biliary 10%
Renal: ~70% unchanged; Biliary/Fecal: ~20% as metabolites
Category C
Category C
Oral Contraceptive
Oral Contraceptive